Even with the cheaper entry price, we're sitting this one out for now. Here are three reasons why there are better opportunities than TXG and a stock we'd rather own. Founded in 2012, 10x Genomics ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 ...

TXG) stock increased significantly by 33% over the... Compelling results return multiple high-grade intercepts at both Media Luna East and West (All amounts expressed in U.S. dollars unless ...